Rei Ishibashi

774 citations
33 papers · 574 indexed · h-index 14
Topics
Circular RNAs in diseases (6 papers)Colorectal Cancer Surgical Treatments (5 papers)Esophageal and GI Pathology (5 papers)
Journals
SHILAP Revista de lepidopterologíaGastroenterologyHepatology
Partner nations
JapanGermanyChina

In The Last Decade

Rei Ishibashi

31 papers receiving 564 citations

Peers

Rei Ishibashi
Comparison fields: 5 of 66
  • Molecular Biology 257
  • Epidemiology 174
  • Cancer Research 158
  • Oncology 146
  • Surgery 107
Replace Toshiyuki Morisawa with:
Toshiyuki Morisawa Japan
Marshall Miller United States
Ritsuko Oikawa Japan
Mei Kong China
Iranzu González Spain
Lorenzo Pacenti Italy
Thomas L. Haulk United States
Tetsuro Urashima Japan
Julien Fernandes France
Joanna H. Maltbaek United States
Rei Ishibashi relative to Toshiyuki Morisawa Japan Toshiyuki Morisawa's profile →
Citations per field
00.5×8.7×
Toshiyuki Morisawa · 1×
Citations per year

Countries citing papers authored by Rei Ishibashi

Since Specialization
Citations

This map shows the geographic impact of Rei Ishibashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rei Ishibashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rei Ishibashi more than expected).

Fields of papers citing papers by Rei Ishibashi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rei Ishibashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rei Ishibashi. The network helps show where Rei Ishibashi may publish in the future.

Co-authorship network of co-authors of Rei Ishibashi

This figure shows the co-authorship network connecting the top 25 collaborators of Rei Ishibashi. A scholar is included among the top collaborators of Rei Ishibashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rei Ishibashi. Rei Ishibashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 1
3 15
4 5
5 10
6 2
7 2
8 2
9 19
10 82
11 11
12 5
13 2
14 15
15 3
16 88
17 34
18 17
19 19
20 60

About Rei Ishibashi

Rei Ishibashi is a scholar working on Oncology, Hepatology and Cancer Research, having authored 33 papers that have together received 574 indexed citations. Recurring topics across this work include Circular RNAs in diseases (6 papers), Colorectal Cancer Surgical Treatments (5 papers) and Esophageal and GI Pathology (5 papers). The work is most often cited by research in Gastroenterology (71 citations), Hepatology (102 citations) and Cancer Research (158 citations). Rei Ishibashi has collaborated with scholars based in Japan, Germany and China. Frequent co-authors include Kazuhiko Koike, Motoyuki Otsuka, Takahiro Kishikawa, Mari Yamagami, Motoko Ohno, Kazuma Sekiba, Tatsunori Suzuki, Takahiro Seimiya, Eri Tanaka and Akemi Takata. Their work appears in journals such as SHILAP Revista de lepidopterología, Gastroenterology and Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026